Movement Alert｜Guardant Health Rises 5.21% in Regular Trading, BofA Raises Price Target to $190

Market Focus07-09

On July 9, Guardant Health rose 5.21% in regular trading, trading at $169.07/share, with turnover of $130 million. The move was driven by BofA Securities significantly raising its price target on the stock from $135 to $190 while maintaining a Buy rating.

The upgrade reflects a series of fundamental catalysts. The company has secured multiple FDA approvals in recent months, including Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer and colorectal cancer therapies, and Guardant360 CDx for HER2-mutant advanced NSCLC. Its Shield blood test was also included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. Q1 revenue of $301.7 million beat the $279.2 million consensus estimate, while adjusted EPS of -$0.45 significantly outperformed the -$0.76 estimate. Full-year revenue guidance was raised to $1.30-1.32 billion, above the prior FactSet estimate of $1.27 billion. RBC Capital Markets and Evercore ISI have also initiated or upgraded coverage with bullish targets, citing the underpenetration of genomic profiling as a key growth opportunity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130046617?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130046617","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 5.21% in Regular Trading, BofA Raises Price Target to $190","media":"Market Focus","content":"<p><p>On July 9, Guardant Health rose 5.21% in regular trading, trading at $169.07/share, with turnover of $130 million. The move was driven by BofA Securities significantly raising its price target on the stock from $135 to $190 while maintaining a Buy rating.</p><p>The upgrade reflects a series of fundamental catalysts. The company has secured multiple FDA approvals in recent months, including Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer and colorectal cancer therapies, and Guardant360 CDx for HER2-mutant advanced NSCLC. Its Shield blood test was also included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. Q1 revenue of $301.7 million beat the $279.2 million consensus estimate, while adjusted EPS of -$0.45 significantly outperformed the -$0.76 estimate. Full-year revenue guidance was raised to $1.30-1.32 billion, above the prior FactSet estimate of $1.27 billion. RBC Capital Markets and Evercore ISI have also initiated or upgraded coverage with bullish targets, citing the underpenetration of genomic profiling as a key growth opportunity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 5.21% in Regular Trading, BofA Raises Price Target to $190</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 5.21% in Regular Trading, BofA Raises Price Target to $190\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-09 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 9, Guardant Health rose 5.21% in regular trading, trading at $169.07/share, with turnover of $130 million. The move was driven by BofA Securities significantly raising its price target on the stock from $135 to $190 while maintaining a Buy rating.</p><p>The upgrade reflects a series of fundamental catalysts. The company has secured multiple FDA approvals in recent months, including Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer and colorectal cancer therapies, and Guardant360 CDx for HER2-mutant advanced NSCLC. Its Shield blood test was also included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. Q1 revenue of $301.7 million beat the $279.2 million consensus estimate, while adjusted EPS of -$0.45 significantly outperformed the -$0.76 estimate. Full-year revenue guidance was raised to $1.30-1.32 billion, above the prior FactSet estimate of $1.27 billion. RBC Capital Markets and Evercore ISI have also initiated or upgraded coverage with bullish targets, citing the underpenetration of genomic profiling as a key growth opportunity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1130046617","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130046617","pubTimestamp":1783606488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 9, Guardant Health rose 5.21% in regular trading, trading at $169.07/share, with turnover of $130 million. The move was driven by BofA Securities significantly raising its price target on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"走势警报|Guardant Health 常规交易中上涨 5.21%，美国银行将目标价上调至 190 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 9, Guardant Health rose 5.21% in regular trading, trading at $169.07/share, with turnover of $130 million. The move was driven by BofA Securities significantly raising its price target on the stock from $135 to $190 while maintaining a Buy rating.The upgrade reflects a series of fundamental catalysts. The company has secured multiple FDA approvals in recent months, including Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer and colorectal cancer therapies, and Guardant360 CDx for HER2-mutant advanced NSCLC. Its Shield blood test was also included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. Q1 revenue of $301.7 million beat the $279.2 million consensus estimate, while adjusted EPS of -$0.45 significantly outperformed the -$0.76 estimate. Full-year revenue guidance was raised to $1.30-1.32 billion, above the prior FactSet estimate of $1.27 billion. RBC Capital Markets and Evercore ISI have also initiated or upgraded coverage with bullish targets, citing the underpenetration of genomic profiling as a key growth opportunity.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130046617","isCrawlerRequest":true}